Cannabis Wellness Startup Awshad Launches Its Cannabis Medicinal Capsules Named 'Calmasule'

Delhi-based cannabis wellness startup Awshad has announced the launch of their new prescription product - a cannabis medicinal capsule line branded as ‘Calmasule’. The objective behind this roll-out of the new product line of Awshad is to help people experience the healing qualities of cannabis in the form of a capsule in order to enable them to alleviate pain, insomnia, stress and various other lifestyle ailments through an all-natural solution and thus aid their overall well-being. Interestingly, the naming of Calmasule is inspired by the first and foremost effect of this capsule, which is to calm down one’s nerves to further help an individual with managing anxiety, pain and sleep issues.

With this new line of products, Awshad intends to expand its target audience and customer base and thereby increase sales and revenue in order to consolidate market leadership. Thisin turn will help Awshad infuse more resources in educating and spreading awareness to destigmatize cannabis and spread awareness on its myriad wellness benefits, which till date remains the biggest hurdle in this industry.

Awshad has been working with leading cannabis manufacturing and formulation teams in India in a bid to come out with these superlative, pure cannabis extract capsules that have been proven to have very high efficacy and showed extremely promising results amongst the focus groups. Only if and when they have a prescription, the customers would be able to buy Awshad’s newly-launched capsule products directly from the Awshad website or via aggregator marketplaces like CBD Store, It’s Hemp and others.

Awshad’s new range of capsules have been made available under two variants: Calmasule and Calmasule Plus; the main difference between these two variants lies in the concentration/ratio of CBD and THC (both of them being compounds present in cannabis) present in the product. Calmasule is the milder product variant which is more versatile and can be used by a wide range of users. With 10mg CBD and 5mg THC (2:1 CBD: THC ratio), Calmasule helps patients combat anxiety, stress, insomnia and mild pain issues. On the other hand, Calmsule+ is a much stronger product variant with 15mg CBD and 15mg THC (1:1 CBD: THC ratio), thus especially recommended for those facing chronic and more serious ailments like chronic pains, chronic insomnia, Cancer, Parkinson’s, Epilepsy, Arthritis, etc.

Speaking on the launch of the new product, Shivam Singhee, Co-Founder & CEO, Awshad said, “We at Awshad are extremely pleased and excited to introduce our and India’s first cannabis extract-based capsules to the market, called Calmasule and Calmasule Plus. These newly-launched Awshad capsules are meant to derive the best efficacy and results for our discerning Indian customers. Also, these capsules will be the strongest products among our current offerings, and is geared towards people who are looking for highly effective products to deal with their more serious ailments. In the long run, we understand the importance of a variety of products under a trusted brand can lead to bigger market acceptance, and knowing that our customers come from diverse backgrounds and situations, we shall continue to strive to serve them all with appropriate products that will help them achieve their health and wellness goals.”

Richa Jaggi, Co-Founder & CMO, Awshad adds, “As a brand in a nascent industry, it is imperative that we continue to innovate and our biggest inspiration comes from our customers and we always listen to what they require from us. Some of our customers wanted an easier to carry and an easier product to administer (instead of using the dropper for Vijaya Oils). And we also found out that a lot of people are more comfortable with capsules and pills over edible tinctures. We further recognized that we were interacting with a lot of people who are looking for stronger cannabis products in the market, as the current offering isn’t satisfying their needs. Following these findings and active listening to our customers’ feedback, we are glad to now introduce Awshad’s new medicinal cannabis capsules. Looking at the growing acceptance in the market, we are very certain Calmasule will create a huge demand in the Indian cannabis space and help Awshad to consolidate its leadership in the Indian medical cannabis space.”

Notably, Awshad’s dynamic website has multiple onboarded in-house doctors who can help patients to get valid prescriptions for the product, and would also diagnose and provide answers to any queries a patient may have. If one already has a valid prescription, he/she can simply upload the prescription during the checkout process while purchasing the product on the Awshad website.

Previously, Awshad had also launched its flagship prescription product named ‘Awshad Full Spectrum Vijaya Oil’. While Awshad’s Vijaya Oil product offers more value for money and last longer for the consumers, but their latest offering, i.e. the Calmasule capsules are meant for people who prefer pills over edible oils. The Awshad capsules have no taste, are easy to swallow, and would help people with more consistent dosages. In the near future, Awshad will continue to innovate constantly with newer formats of medical cannabis while attempting to move closer to their vision of revolutionizing the wellness sector in India. Notably, all of Awshad’s products are intensively lab-tested and certified by the Ministry of AYUSH, Government of India.

About Awshad

Awshad is a South-Delhi based cannabis wellness startup co-founded and bootstrapped by Shivam Singhee, CEO and Richa Jaggi, CMO. Awshad’s clinically-tested, vegan and gluten-free Full-Spectrum CBD products are made using the highest quality cannabis extract in a bid to provide better health and wellness to people across all ages and backgrounds. However, the products are especially targeted towards those dealing with lifestyle ailments such as stress, insomnia, anxiety, chronic pain, epilepsy and inflammation, among various other lifestyle issues. The startup works with the objective and vision to revolutionize the wellness space in India, while providing profound and long-term physical and mental health and wellness benefits to their customers.

HempStreet Expands Product Portfolio, Launches Sarpagandha Vati, to Combat Hypertension

HempStreet, India's first research to retail venture in the ayurvedic cannabis sector, has launched Sarpagandha Vati. Coming in the form of a tablet, Sarpagandha Vati helps treat Hypertension and Insomnia due to its calmative properties.

HempStreet’s dispensation works through a network of doctors who can buy the product via HempStreet’s B2B channels. This medicine is safe and reliable for middle and even old age people (39-70 years) who are at higher risk of side effects. The classical ayurvedic formulation outperforms other drugs in the same therapeutic range when combined with more potent herbs such as Vijaya (Cannabis Sativa) and Jatamansi (Nardostachys Jatamansi).

Each tablet of ‘Sarpagandha Vati’ contains Sarpagandha (262.20 mg), Khurasani Ajwain (52.44 mg), Jatamansi (26.22 mg), Vijaya (26.22 mg) and Pipalimula (4.92 mg). This Ayurvedic medicine calms the nervous system, aids in the maintenance of normal blood pressure, and maintains oxygen balance that helps regulate blood pressure in hypertensive patients. Additionally, Sarpagandha Vati’s diuretic and detoxifying properties benefit people with the following health and lifestyle issues:

• Help manage Epilepsy and Delirium
• Help combat anxiety disorder
• Help curb the desire for Alcohol
• Induce natural sleep to defy Insomnia

While conventional medications have serious health consequences, Ayurveda offers a natural, holistic, safe, and effective alternative to alleviate the condition of Hypertension. Sarpagandha Vati aims at providing a reliable and safe ayurvedic solution to hypertensive patients by regulating their blood pressure.

About HempStreet

HempStreet is India's first research to retail medicinal cannabis venture, working towards amalgamating the age-old science of Ayurveda with modern cannabis research to develop sustainable and economical solutions for mass ailments. All of this while ensuring end-to-end blockchain technology-based supply chain tracking to minimize any chance of abuse. HempStreet's dispensation network of more than 11000 partner clinics across 26 states of India is a testament to the efficacy of the formulations and the trust of medical practitioners in the brand. 

The company is also India's first medicinal cannabis venture to have been awarded the prestigious Biotechnology Ignition Grant (BIG) of BIRAC. Recently HempStreet partnered with Gynica, an R&D company based out of Israel focused on changing the culture of gynecological treatment through clinically proven, cannabinoid-based solutions.

Greek Billionaire Launches World's 1st Cannabis-tied Cryptocurrency and Wallet

Greek billionaire Alkiviades David, who owns substantial shareholding of Leventis-David Group, which owns Coca-Cola Hellenic bottling plants in 28 countries, and his Swiss-based consortium have launched The Swissx Bank of Cannabis and world's first cannabis-tied cryptocurrency and global hemp exchange in the world, in a bid to ease global marijuana transactions.

Headquartered in Gstaad, the Bank operates cryptocurrency SWX Coin with wallet Swissx wallet and Global Hemp Exchange. SWX Coin is a cryptocurrency based on blockchain technology of Bitcoin and its single unit pricing is decided directly by global price of premium hemp flower.

The Swissx Global Hemp Exchange will also provide the entire industry with a secondary market where futures and other trades can be made based on its global market analytics.

Initially the bank and its coin will manage all of Swissx’s financial transactions with its many partners in the United States, Europe and the Caribbean, but the bank is also a turn-key solution for the entire Cannabis sector, providing a secure, transparent venue for all transactions, and a coin tied to a commodity. The CBD-hemp business is expected to reach $24 billion in the U.S. alone by 2023.

Moreover, Nevis Denzil Douglas, who is former Prime Minister of Caribbean island St. Kitts, has also joined the Swissx Bank of Cannabis board. Douglas, who is also known as the Founder and CEO of his social and environmental impact non-profit, the Global Lifestyle Group, has already been acting as a Caribbean business development consultant for Swissx.

The Swissx Bank of Cannabis and the Swissx Global Hemp Exchange will soon name a Caribbean capitol as regional headquarters from a shortlist of competing offers.

The Swissx Bank of Cannabis launched with the backing of $750 million dollars worth of premium Swissx Cherry Wine and Donald Trump seeds and $250 million in Swiss Francs. The Farmer’s Wallet within the SWX Coin block-chain has been set up to pay members of the Swissx Hemp Farmers’ Cooperative. The international cooperative, which is growing quickly across the Caribbean, was set up to keep up with the demand for Swissx Hemp Flower products, and provides proprietary hemp strains, training, and a guarantee to purchase all crops grown by its participating farmers.

Farmers are paid in SWX Coin from the Farmer’s Wallet which is redeemable for cash anytime, without restriction, from the bank’s vaults in Gstaad, Switzerland or regional offices in the Caribbean. Outside of the Farmer’s Wallet, surplus hemp is sold to third party buyers using SWX Coins that they purchase from Swissx Bank of Cannabis.

Though in very early and premature stage, the Swissx Global Hemp Exchange also plans to monitor and analyze thousands of data streams including predictive crop software linked to partner Chase Ergen’s vast network of satellites, EchoStar. The Exchange will initially handle Swissx’s surplus crop at preferred rates but will eventually become the authority for the entire Cannabis sector for trusted pricing and trading.

For added speed and security the Swissx Bank of Cannabis and SWX Coin operate on D-Wave Technology's advanced quantum computers.

Swissx, the first company to take safe, legal, CBD products into the mainstream, has recently developed a massive international cooperative farming operation with acres already planted in California and Puerto Rico, and 5000 more acres under contract across the Caribbean. Swissx CBD products are distributed globally in premium health food stores, doctors offices, and in mass market outlets such as 7-11 convenience stores. The products have been endorsed by Mike Tyson, Scott Disick, of Keeping up with the Kardashians, Dave Navarro of the Red Hot Chili Peppers, Snoop Dogg, Chief Keef, Lil Wayne, Tommy Chong of Cheech and Chong, Donatella Versace, Jonathan Rhys Myers and many more.

Swissx Genetics, with labs in Switzerland and South Korea, has developed the purest and most powerful CBD-only strains of hemp available and Head of Genetics Dr. Olof Olson continues to modify using genetic modification and some highly unconventional radiation-based experiments to continue to develop a strain so distinctive it becomes its own genus. (The division of Swissx is also working on animal cloning and de-extinction).

[caption id="attachment_132319" align="aligncenter" width="768"] Alki David, CEO of Swissx, with former St. Kitts-Nevis Prime Minister Denzil Douglas (left), who is on the board of the Swissx Bank of Cannabis. Pictured with the Swissx Express jet and Vader, David's Doberman who is the subject of a Swissx Genetics breakthrough cloning project.[/caption]

Alki David’s efforts in the Caribbean have been praised by agricultural and business leaders, as well as government officials, for their fairness and their urgency.

“First we changed the game for CBD products, then we created tremendous opportunity for farmers and their regional economies throughout the Caribbean," said Alki David, CEO and Founder of Swissx. “Now we’ve used Swiss financial know-how to create the first bank and cryptocurrency entirely optimized for the legal cannabis industry. The Swissx Global Exchange will be an authoritative resource for the entire industry, better than Nielsen, bigger than Nasdaq. Together, the Bank and Currency and Exchange don’t just insure Swissx’s international operations run perfectly, it will become the engine for the fastest growing business sector in the world.”

Swissx is supported by Alki David’s companies, FilmOn Networks, a pioneering, global streaming TV service, Hologram USA, the original celebrity hologram and telepresence company, and the digital distribution platform Octiive. Partners of Alki David’s companies include Universal Studios, Capital Cities/ABC, the House of Dior, Universal Music Group, Tyson Ranch, Indian Prime Minister Narendra Modi, NBCUniversal, and many more.

Swissx Farming Cooperative Program

Swissx is working to provide everything needed to maximize returns in the globe's fastest growing market in order to maximize the benefits of progressive legal change sweeping the world.

Seeing the value in setting up infrastructure and knowledge around cannabis growing Swissx and its partners offers best practices in planting, tending and harvesting, by teachings from experts who have decades of growing experience around the world.

Swissx even paying for the highest quality seeds specially calibrated for market needs and the soil and microclimate being farmed. The company manages all quality control from seed to harvest--there is no guess work on the partners teach best practices in planting, tending and harvesting, as gathered by our experts who have decades of growing experience around the world.

Alki David, CEO of Swissx, says, “The Caribbean can and will be the Wall Street of Cannabis, the Silicon Valley, the Hollywood. The time to move on this is now."

India's CSIR Gets License for "Cannabis" Medical Research, To Launch Two Breakthrough Drugs

In next one-year, India will have its own indigenously developed and manufactured Cannabis-based medicinal drugs as three major science R&D bodies in India -- The Council of Scientific and Industrial Research (CSIR), the Indian Council for Medical Research and the Department of Biotechnolgy -- are getting together to promote research in herbal drugs, some of which involve deriving new drugs from marijuana.

CSIR’s Indian institute of Integrative Medicine (IIIM), Jammu has recently been granted license for cultivation of "Cannabis" for medical research and drug development, to conduct study to explore its potential clinical benefits. To conduct research on "Medical Marijuana" drugs, IIIM has tied up with Tata Memorial Hospital, whereas tests for the epilepsy drug will be conducted in New Delhi’s AIIMS.

Manufactured locally in India and available in next one year, the new hemp-based medicines will be for cancer pain management and epilepsy treatment and CSIR is said to be in advanced stage of clinical trials to launch two new drugs based on Marijuana.

[caption id="attachment_127406" align="aligncenter" width="800"] Union Minister Dr Jitendra Singh at the Conference on medical use of Cannabis in India held in Delhi.
(Image - Twitter.com/DrJitendraSingh)[/caption]

Ratan Tata-backed cannabis research startup, Bombay Hemp Company (BOHECO), is CSIR’s funding partner for the two research projects and is expected to market the drugs in India. BOHECO, which studies the medical uses of cannabis, had raised raised $1 million from a group of investors led by Ratan Tata, chairman emeritus of Tata Sons and Rajan Anandan, Google India’s managing director, Sanvar Oberoi

The two new breakthrough drugs are based on cannabidiol (CBD) — one of the two primary compounds occurring naturally in the cannabis sativa plant. CBD is non-psychoactive, meaning it will not deliver a high to the user. The other compound is Tetrahydrocannabinol (THC). Such drugs are being used in the US and Europe but their distribution in India will bring down the cost of the formulations currently needing specific clearances.

The related organisations were in the process of formally applying to the Drug Control General of India for permissions.

A 2013 study published in the British Journal of Clinical Pharmacology found that CBD benefits include acting as an anti-inflammatory, anti-convulsant, anti-oxidant, an antipsychotic agent, and is, therefore, an effective treatment for such disorders as inflammation, oxidative injury, epilepsy, nausea and vomiting.

In the recent past, we have seen how Marijuana has made its way into the medical mainstream in Western countries however in India, there is different thing altogether as patients in India are denied cannabis-based medicines due to strict regulations.

The studies into the therapeutic potential of marijuana is part of a larger governmental thrust to making new drugs derived from herbs and plants that find mention in Ayurvedic and other traditional-medicine knowledge systems.

Source - Hindu, Times of India